MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. MEDI4736 shows antitumor activity in xenograft mouse models of human cancer.

Slides:

Advertisements

Similar presentations

Synergistic antitumor effect of anti-CD40/CpG and 14

Advertisements

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

MI-773 reduces the fraction of CSCs and prevents recurrence in ACC xenograft tumors. MI-773 reduces the fraction of CSCs and prevents recurrence in ACC.

BAP1 deficiency results in thymic atrophy and loss of thymocyte populations. BAP1 deficiency results in thymic atrophy and loss of thymocyte populations.

PD-1 blockade results in increased expression of the chemokine receptor CXCR3. PD-1 blockade results in increased expression of the chemokine receptor.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Exosome-mediated inhibition of T cells is reversible.

CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.

Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model. TH-302 has antileukemia activity in an in vivo primary AML xenograft.

CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition.

Antitumor immunity caused by DS-8201a.

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

Antitumor activity of KM100+5 μmol/L MTX treatment in the presence or absence of CD8+ T cells in BALB-neuT mice bearing subcutaneous tumors of TUBO cells.

SBC-5 miR-335+ xenografts abrogated completely, or in part, skeletal osteolytic lesions in humanized NOD/SCID IL2Rγnull immunodeficient mice. SBC-5 miR-335+

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

Quercetin induces arrest in G1 phase of cell cycle in P39 xenografts.

Quercetin induces apoptosis in P39 xenografts.

Depletion of UCP1 and Myf5 population reduced xenograft growth.

Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.

Active AR signaling in enzalutamide-resistant xenograft tumors.

Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.

Antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against xenograft models sensitive.

The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.

Endothelial cells/microvasucles are increased in prostate cancer versus normal tissues. Endothelial cells/microvasucles are increased in prostate cancer.

ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells, and NK cells. ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells,

Antitumor effects of celastrol in vitro and in vivo.

Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ) in vivo. Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ)

Effect of nivolumab or ipilimumab on immune responses to vaccination in cynomolgus monkeys. Effect of nivolumab or ipilimumab on immune responses to vaccination.

Effect of the crystal form and solid dispersion preparations of KRN633 on the growth of human tumor xenografts in mice. Effect of the crystal form and.

Essential role for the overexpression of type I IFN-related genes in the improved chemotherapeutic response of Stat3−/− tumors. Essential role for the.

PD-1 expression in ovarian cancer.

Determination of MTD for romidepsin and pralatrexate and associated antitumor activity. Determination of MTD for romidepsin and pralatrexate and associated.

A, inhibition of FGF2 binding to the FGFR by porphyrin analogues.

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

Systemic reovirus treatment targets disseminated human myeloma in vivo

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

Anti-SEMA4D antibody regulates immune-cell infiltration and inhibits growth of Tubo.A5 orthotopic mammary carcinoma. Anti-SEMA4D antibody regulates immune-cell.

Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.

Effect of dietary feeding of silibinin on DU145 tumor xenograft growth in athymic male nude mice. Effect of dietary feeding of silibinin on DU145 tumor.

Expression of HO-1 by the FAP+/F4/80+ tumoral macrophages.

CPI-444 enhances T-cell activation in MC38 tumors.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Trametinib and combination promote moDC maturation and decrease moDC viability. Trametinib and combination promote moDC maturation and decrease moDC viability.

Mean percentage change from baseline in total IGF-I and the R1507 serum concentration values following a single i.v. administration of R mg/kg (n.

Mean body weights (grams) of athymic female mice implanted with MDA-MB-231 breast carcinoma xenografts. Mean body weights (grams) of athymic female mice.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

RhuαVEGF and rhuαVEGF/paclitaxel mediated growth inhibition in an androgen-independent prostate cancer xenograft model. rhuαVEGF and rhuαVEGF/paclitaxel.

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

PDL192 and inhibit the growth of xenograft tumors.

A, antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against “sensitive” Ewing.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.

MPD-L1–transfected 300 cells do not bind to mB7-1–transfected 300 cells. mPD-L1–transfected 300 cells do not bind to mB7-1–transfected 300 cells. Cell-to-cell.

CPI-444 synergizes with anti–PD-L1 and anti–CTLA-4 treatment.

Ex vivo profiling of PD-1 blockade using MDOTS

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

MDSC population in patient peripheral blood.

Comparison of PD-L1 mAbs in IHC across multiple tumor types.

RIL21 and checkpoint blockade restore IFNγ production in Tim-3+PD-1+ intratumoral NK cells from cancer patients. rIL21 and checkpoint blockade restore.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Presentation transcript:

MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. A, fluorescence observed on HPAC and A375 cell lines by flow cytometry following staining with an anti–PD-L1 (filled) antibody or an isotype control antibody (dotted). B, HPAC tumor volumes (mm3) in NOD/SCID mice following coimplantation of primary human T cells and administration of MEDI4736 i.p. at 5, 1, 0.1, and 0.01 mg/kg twice per week for 3 weeks as indicated. C, A375 tumor volumes (mm3) in NOD/SCID mice following coimplantation of primary human T cells and administration of MEDI4736 i.p. at 5, 1, and 0.1 mg/kg twice per week for 3 weeks as indicated. D, A375 tumor volumes (mm3) in NOD/SCID mice without coimplantation of primary human T cells and administration of MEDI4736 i.p. at 1 and 0.1 mg/kg twice per week for 3 weeks as indicated. *, P ≤ 0.05 as determined by a Mann–Whitney rank sum test. Ross Stewart et al. Cancer Immunol Res 2015;3:1052-1062 ©2015 by American Association for Cancer Research